Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilmi Kodaz

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Medicina (Kaunas, Lithuania)|June 26, 2026
Immunosuppressive Tumor Microenvironment Signatures Predict Early Progression in NSCLC Patients Receiving Immune Checkpoint Inhibitors: A Transcriptomic and Immune Deconvolution Analysis of GSE135222Hilmi Kodaz, Çağnur Elpen Kodaz, Gökhan Öztürk, et al.
JPMA. the Journal of the Pakistan Medical Association|March 16, 2018
Metaplastic breast cancer: A case reportSerdar Surenkok, Emre Tahberer, Ahmet Cinkaya, et al.
Tumori|July 1, 2017
Effect of delayed radical cystectomy for invasive bladder tumors on lymph node positivity, cancer-specific survival and total survivalHakan Türk, Sıtkı Ün, Ahmet Cinkaya, et al.
Journal of Cancer Research and Therapeutics|September 11, 2018
The factors that affect the prediction of lymph node metastasis in prostate cancerHakan Turk, Sıtkı Ün, Osman Koca, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 1, 2015
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance statusIlhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, et al.
Tumori|February 24, 2015
Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancerHilmi Kodaz, Ilhan Hacibekiroglu, Esma Turkmen, et al.
Hepato-Gastroenterology|February 24, 2016
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer PatientsHilmi Kodaz, Bulent Erdogan, Ilhan Hacibekiroglu, et al.
Acta Gastro-Enterologica Belgica|July 8, 2016
Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatmentEsma Turkmen, Bulent Erdogan, Hilmi Kodaz, et al.
European Radiology|November 14, 2013
Incidence of contrast-induced nephropathy in hospitalised patients with cancerIrfan Cicin, Bulent Erdogan, Emrah Gulsen, et al.
Molecular and Clinical Oncology|December 2, 2015
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancerIlhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Medicina (Kaunas, Lithuania)|June 26, 2026
Immunosuppressive Tumor Microenvironment Signatures Predict Early Progression in NSCLC Patients Receiving Immune Checkpoint Inhibitors: A Transcriptomic and Immune Deconvolution Analysis of GSE135222Hilmi Kodaz, Çağnur Elpen Kodaz, Gökhan Öztürk, et al.
JPMA. the Journal of the Pakistan Medical Association|March 16, 2018
Metaplastic breast cancer: A case reportSerdar Surenkok, Emre Tahberer, Ahmet Cinkaya, et al.
Tumori|July 1, 2017
Effect of delayed radical cystectomy for invasive bladder tumors on lymph node positivity, cancer-specific survival and total survivalHakan Türk, Sıtkı Ün, Ahmet Cinkaya, et al.
Journal of Cancer Research and Therapeutics|September 11, 2018
The factors that affect the prediction of lymph node metastasis in prostate cancerHakan Turk, Sıtkı Ün, Osman Koca, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 1, 2015
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance statusIlhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, et al.
Tumori|February 24, 2015
Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancerHilmi Kodaz, Ilhan Hacibekiroglu, Esma Turkmen, et al.
Hepato-Gastroenterology|February 24, 2016
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer PatientsHilmi Kodaz, Bulent Erdogan, Ilhan Hacibekiroglu, et al.
Acta Gastro-Enterologica Belgica|July 8, 2016
Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatmentEsma Turkmen, Bulent Erdogan, Hilmi Kodaz, et al.
European Radiology|November 14, 2013
Incidence of contrast-induced nephropathy in hospitalised patients with cancerIrfan Cicin, Bulent Erdogan, Emrah Gulsen, et al.
Molecular and Clinical Oncology|December 2, 2015
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancerIlhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, et al.
Pageof 3